---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011636"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:01:06.047616+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Viking Therapeutics closes $287.5M public offering of 19.8M shares at $14.50/share

## Summary
- Gross proceeds of approximately $287.5 million from 19,828,300 shares at $14.50 per share.
- Underwriters' option to purchase 2,586,300 additional shares exercised in full.
- Net proceeds to fund VK2809, VK2735, VK0214 programs and general corporate purposes.
- William Blair & Co. served as lead book-runner; Raymond James as joint book-runner.

## SEC filing metadata
- accession: 0000950170-23-011636
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017023011636/0000950170-23-011636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017023011636/vktx-20230403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011636
- JSON: https://secwatch.observer/filing/0000950170-23-011636.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.